Hepatocellular carcinoma (HCC) presents significant treatment challenges despite
considerable advancements in its management. The Indian National Association for the …

Highlights•Liver cancer, a global threat, ranks sixth in incidence and is the second-leading
cause of cancer fatalities.•Despite effective treatments, issues like affordability and …

Interim analysis of the DOSISPHERE-01 study demonstrated a strong improvement in
response and overall survival (OS) on using 90Y-loaded glass microspheres with …

BACKGROUND Hepatic arterial infusion chemotherapy (HAIC) has been proven to be an
ideal choice for treating unresectable hepatocellular carcinoma (uHCC). HAIC-based …

Transarterial radioembolization (TARE) with Yttrium-90 (Y90) is a growing area of study due
to its benefits in early-, intermediate-, and late-stage hepatocellular carcinoma. Treatment …

Human epidermal growth factor receptor 2 (HER2) status is used for decision-making in
breast carcinoma treatment. The status is obtained through immunohistochemistry or in situ …

Deaths from the majority of cancers are falling globally, but the incidence and mortality from
hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western …

Hepatocellular carcinoma (HCC) accounts for over 90% of primary liver cancers, is the sixth
most common malignancy globally, and is the third most common cause of cancer-related …

Background Hepatocellular carcinoma is one of the most common malignancies worldwide.
Transarterial radioembolisation (TARE) involves selective intra-arterial administration of …

2 a LC rate of 100% at 1 and 2 years, which was more than double the LC rate of TACE (p=
0.019). The worse LC of TACE may be attributable to treatment-induced damage to …